Magic mushrooms meet opioid treatment: a safety check
NCT ID NCT04161066
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 27 times
Summary
This early-stage study tests whether adding two doses of psilocybin (the active ingredient in magic mushrooms) to standard buprenorphine/naloxone treatment is safe for adults with opioid use disorder. Ten participants will be closely monitored for side effects and changes in withdrawal symptoms, cravings, and quality of life. The goal is to see if psilocybin can safely support recovery without causing harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
Contact
Conditions
Explore the condition pages connected to this study.